Research·October 23, 2026 at 3:45 AM EDT·2 sources
STAT+: Alnylam says Huntington’s drug shows promise in early study
ALNY -1.4%
ALNY · last 30 trading days-0.5% since the news
News
What happened
- Alnylam said its RNA drug for Huntington’s disease showed promising early-study results.
- The drug’s ability to slow Huntington’s progression remains unproven, and Alnylam plans a larger study.
- Roche’s recent study showed that promising biomarker data did not translate into clinical benefits.
Why it matters
The results highlight both the potential and clinical-development risk in Huntington’s disease drug development, an area closely watched by healthcare investors and biotech professionals.
What to watch. Alnylam’s planned larger study of the Huntington’s disease drug.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- First reported by STATOct 23STAT+: Alnylam says Huntington’s drug shows promise in early study
- Endpoints News reportsOct 23Alnylam plans bigger study of RNA drug for Huntington’s disease
Who is involved
STAT+: Alnylam says Huntington’s drug shows promise in early …Alnylam PharmaceuticalsALNYRoche
Company
Sources (2)
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.